Inhibition of berberine on IKr, IKs and I Kl in thyroxine induced cardiomyopathic guinea pig ventricular myocytes

Journal of China Pharmaceutical University

Volumn 40, Issue 3, 2009, Pages 244-249

  Yu, Feng ^a   Lin, Mu Sen ^a   Zhang, Wei Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Berberine; Cardiomyopathy; I Kl; IKr; IKs; Patch clamp techniques; Thyroxine

Indexed keywords

BERBERINE; DELAYED RECTIFIER POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTRIC POTENTIAL; GUINEA PIG; HEART MUSCLE CELL; HEART VENTRICLE; IC 50; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; WHOLE CELL;

EID: 67650799447     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lopshire JC, Zipes DP. Sudden cardiac death : better understanding of risks, mechanisms, and treatment[J]. Circulation,2006,114(11):1134-1136.
2. Yu F, Dai DZ, An LF, et al. Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats[J]. Acta Pharmacol Sin,1997,18(1):71-74.
3. Dai DZ, Yu F. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias[J]. Acta Pharmacol Sin,2005,26(8):918-925.
4. Furukawa T, Kurokawa J. Potassium channel remodeling in cardiac hypertrophy[J]. J Mol Cell Cardiol,2006,41(5):753-761.
5. Dai DZ. The anti-arrhythmic activity of protoberberines in relation to blockade of ion channels[J]. Ion Channel Modulators, 1997,2(10):383-390.
6. Lau CW, Yao XQ, Chen ZY. Cardiovascular actions of berberine[J]. Cardiovasc Drug Rev,2000,19(3):234-244.
7. Li B, Zhu WL, Chen KX. Acta Pharm Sin, 2008,43(8):773-787.
8. Kl, and HERG channels of cardiac myocytes[J]. Acta Pharmacol Sin,2001,22(2):125-131.
9. Li N, Yang L, Dai DZ, et al. Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less α-adrenoceptor antagonism[J]. Clin Exp Pharmacol Physiol,2008,35(8):643-650.
10. Rees SA, Vandenberg J I, Wright AR, et al. Cell swelling has differential effects on the rapid and slow components of delayed rectifier potassium current in guinea pig cardiac myocytes[J]. J Gen Physiol,1995,106(6):1151-1170.
11. + current, on repolarization in human and guinea pig ventricular myocytes[J]. Cardiovasc Res,1998,38(2):441-450.
12. + current. Differential sensitivity to block by class III antiarrhythmic agents[J]. J Gen Physiol,1990,96(1):195-215.
13. Ma YP, Zhang GQ, Dai DZ. J China Pharm Univ,2000, 31(2):121-125.
14. Zhang GQ, Ma YP, Dai DZ. J China Pharm Univ,2000,31(6):447-450.
15. Zhang Y, Dai DZ, Feng Y, et al. Downregulated FKBP12. 6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by L-thyroxin[J]. Int J Cardiol,2008,130(3):463-471.
16. Na T, Dai DZ, Dai Y, et al. Abrupt changes in FKBP12. 6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017[J]. Acta Pharmacol Sin,2007,28(6):773-782.
17. Dai DZ. Chin Sci Bull,2008,20(1):69-75.
18. Shah RR. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?[J]. Pharmacol Ther,2008,119(3):215-221.
19. Dai DZ, Hu HJ, Zhao J, et al. Blockade of L-type calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by CPU 86017[J]. Acta Pharmacol Sin,2004,25(4):416-423.
20. Dai DZ. CPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels[J]. Cardiovasc Drug Rev,2006,24(2):101-115.